Amgen Inc

Tweet this page
Registration as it was on 16 Mar 2023
How to read and use this data card.
Download this datacard


Lobbying Costs

1,000,000€ - 1,249,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

2.9 Fte (11)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Amgen Inc

    EU Transparency Register

    42243575237-50 First registered on 07 Feb 2011

    Goals / Remit

    Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen has a presence in approximately 100 countries worldwide. It operates in one business segment : human therapeutics.

    Main EU files targeted

    Engage governments and policy makers worldwide on issues important to Amgen to: Ensure patients have access to medicines they need. Provide coverage and reimbursement that reward innovation
    Introduce sound, science-based regulation. Enable biotechnology research and development (R&D)


    Head Office
    One Amgen Center Drive
    Thousand Oaks, California 91320-1799
    EU Office
    5-7 Telecomlaan


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 24 Mar 2023

    Name Start date End Date
    Ms Viktoria TZOUMA 02 Feb 2023 01 Feb 2024
    Ms Marie Helene FANDEL 26 Feb 2019 01 Feb 2020
    Mr Douglas GREGORY 24 Jan 2019 24 Jan 2020
    Mr Jamie Nathan WILKINSON 20 Nov 2018 20 Nov 2019
    Mr Vincent MARTICHOU 27 Mar 2018 30 Mar 2019
    Ms Marie Helene FANDEL 16 Feb 2018 16 Feb 2019
    Mr Douglas GREGORY 30 Jan 2018 24 Jan 2019
    Mr Douglas GREGORY 25 Feb 2017 30 Jan 2018
    Ms Marie Helene FANDEL 25 Feb 2017 16 Feb 2018
    Mr Janusz LINKOWSKI 05 Sep 2016 26 Aug 2017
    Mr Douglas GREGORY 14 Jan 2016 13 Jan 2017
    Ms Marie Helene FANDEL 16 Sep 2015 14 Sep 2016
    Mr Janusz LINKOWSKI 05 Sep 2015 03 Sep 2016
    Ms JOANA MARIA GANDARA LEITAO PAIVA 23 Jan 2015 23 Oct 2015
    Mr Douglas GREGORY 23 Jan 2015 14 Jan 2016
    Ms JOANA MARIA GANDARA LEITAO PAIVA 15 Mar 2014 23 Jan 2015
    Mr Douglas GREGORY 01 Mar 2014 23 Jan 2015
    Mr Douglas GREGORY 07 Mar 2013 28 Feb 2014

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Companies & groups

  • Networking


    Amgen is a member of the following organizations in Brussels:

    AmCham EU - American Chamber of Commerce to the EU
    EFPIA – European Federation of Pharmaceutical Industries and Associations
    Eucope - European Confederation of Pharmaceutical Entrepreneurs

    EPC - European Policy Centre
    Friends of Europe

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    1,000,000€ - 1,249,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    hanover 100,000€ - 199,999€
    hanover 0€ - 10,000€

    Intermediaries for current year


    Closed year Costs

    1,000,000€ - 1,249,999€

    Other financial info

    Higher estimate of annual costs related to activities covered by the register compared to previous financial year is due to:

    Increased membership fees to organizations

    Increase in percentages of FTEs activity in the scope of the transparency register

    Increased representation costs from intermediaries

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Other activities

    None declared

  • Meetings


    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

    • Date 08 Jul 2022 Location call
      Subject pharmaceutical supply chains
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      • Maurits-Jan Prinz (Cabinet member)
    • Date 12 Jun 2020 Location Videoconference
      Subject Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June)
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      • Ursula von der Leyen (President)
      Other Lobbyists
    • Date 17 May 2018 Location Brussels
      Subject Digital Health
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Digital Economy and Society
      • Manuel Mateo-Goyet (Cabinet member)
Download this datacard